T-cell and B-cell study in children and young adults with antibodies to PEG asparaginase
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how the immune system reacts to a chemotherapy drug called PEG asparaginase in children and young adults. Understanding this could help improve treatment for leukemia by managing or reducing allergic reactions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been treated for acute lymphoblastic leukemia (ALL) with asparaginase.
- You may or may not have had an allergic reaction to the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study examines how your immune system (specifically T cells) reacts to asparaginase, a drug used to treat acute lymphoblastic leukemia. By understanding these reactions, doctors hope to predict and prevent allergic or sensitivity problems during your cancer treatment.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
This study looks at how blood sugar changes in children and teens receiving treatment for ALL (a leukemia) or lymphoma. It focuses specifically on effects that may be caused by steroids and a medicine called PEG-asparaginase.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Hear when a new Acute Lymphoblastic Leukaemia - Category trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.